Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Mar;44(2):119-24.
doi: 10.3164/jcbn.08-220R. Epub 2009 Feb 28.

Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication

Toshihiro Nishizawa  1 , Hidekazu Suzuki, Toshifumi Hibi
Affiliations

Quinolone-Based Third-Line Therapy for Helicobacter pylori Eradication

Toshihiro Nishizawa et al. J Clin Biochem Nutr. 2009 Mar.

Abstract

Currently, a standard third-line therapy for Helicobacter pylori (H. pylori) eradication remains to be established. Quinolones show good oral absorption, no major side effects, and marked activity against H. pylori. Several authors have studied quinolone-based third-line therapy and reported encouraging results, with the reported H. pylori cure rates ranging from 60% to 84%. Resistance to quinolones is easily acquired, and the resistance rate is relatively high in countries with a high consumption rate of these drugs. We recently reported a significant difference in the eradication rate obtained between patients infected with gatifloxacin-susceptible and gatifloxacin-resistant H. pylori, suggesting that the selection of quinolones for third-line therapy should be based on the results of drug susceptibility testing. As other alternatives of third-line rescue therapies, rifabutin-based triple therapy, high-dose proton pump inhibitor/amoxicillin therapy and furazolidone-based therapy have been suggested.

Keywords: Helicobacter pylori; quinolone; third-line therapy.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Primary resistance of H. pylori to quinolone in different countries.
See this image and copyright information in PMC

References

    1. Suzuki H., Hibi T., Marshall B.J. Helicobacter pylori: present status and future prospects in Japan. J. Gastroenterol. 2007;42:1–15. - PMC - PubMed
    1. Suzuki H., Masaoka T., Nomura S., Hoshino Y., Kurabayashi K., Minegishi Y., Suzuki M., Ishii H. Current consensus on the diagnosis and treatment of H. pylori-associated gastroduodenal disease. Keio J. Med. 2003;52:163–173. - PubMed
    1. Asaka M., Sugiyama T., Kato M., Satoh K., Kuwayama H., Fukuda Y., Fujioka T., Takemoto T., Kimura K., Shimoyama T., Shimizu K., Kobayashi S. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter. 2001;6:254–261. - PubMed
    1. Masaoka T., Suzuki H., Kurabayashi K., Kamiya A.G., Ishii H. Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis. Aliment. Pharmacol. Ther. 2004;20 Suppl 1:68–73. - PubMed
    1. Adamek R.J., Suerbaum S., Pfaffenbach B., Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin—influence on treatment outcome. Am. J. Gastroenterol. 1998;93:386–389. - PubMed